• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PI3Kγ 和 PI3Kδ 在恶性 B 细胞迁移中发挥不同作用。

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.

机构信息

Department of Immunology, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada.

Research Institute in Oncology and Hematology, CancerCare Manitoba, 675 McDermot Ave., Winnipeg, MB, R3E 0V9, Canada.

出版信息

Leukemia. 2018 Sep;32(9):1958-1969. doi: 10.1038/s41375-018-0012-5. Epub 2018 Jan 31.

DOI:10.1038/s41375-018-0012-5
PMID:29479062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6127087/
Abstract

The PI 3-kinases (PI3K) are essential mediators of chemokine receptor signaling necessary for migration of chronic lymphocytic leukemia (CLL) cells and their interaction with tissue-resident stromal cells. While the PI3Kδ-specific inhibitor idelalisib shows efficacy in treatment of CLL and other B cell malignancies, the function of PI3Kγ has not been extensively studied in B cells. Here, we assess whether PI3Kγ has non-redundant functions in CLL migration and adhesion to stromal cells. We observed that pharmaceutical PI3Kγ inhibition with CZC24832 significantly impaired CLL cell migration, while dual PI3Kδ/γ inhibitor duvelisib had a greater impact than single isoform-selective inhibitors. Knockdown of PI3Kγ reduced migration of CLL cells and cell lines. Expression of the PI3Kγ subunits increased in CLL cells in response to CD40L/IL-4, whereas BCR cross-linking had no effect. Overexpression of PI3Kγ subunits enhanced cell migration in response to SDF1α/CXCL12, with the strongest effect observed within ZAP70 + CLL samples. Microscopic tracking of cell migration within chemokine gradients revealed that PI3Kγ functions in gradient sensing and impacts cell morphology and F-actin polarization. PI3Kγ inhibition also reduced CLL adhesion to stromal cells to a similar extent as idelalisib. These findings provide the first evidence that PI3Kγ has unique functions in malignant B cells.

摘要

PI3-激酶(PI3K)是趋化因子受体信号转导所必需的关键介质,对于慢性淋巴细胞白血病(CLL)细胞的迁移及其与组织驻留基质细胞的相互作用至关重要。虽然 PI3Kδ 特异性抑制剂idelalisib 在治疗 CLL 和其他 B 细胞恶性肿瘤方面显示出疗效,但 PI3Kγ 在 B 细胞中的功能尚未得到广泛研究。在这里,我们评估了 PI3Kγ 在 CLL 迁移和与基质细胞黏附中是否具有非冗余功能。我们观察到,用 CZC24832 进行药物抑制 PI3Kγ 显著损害了 CLL 细胞的迁移,而双重 PI3Kδ/γ 抑制剂 duvelisib 的影响大于单一同工酶选择性抑制剂。PI3Kγ 的敲低减少了 CLL 细胞和细胞系的迁移。CD40L/IL-4 刺激可使 CLL 细胞中 PI3Kγ 亚基的表达增加,而 BCR 交联则没有影响。PI3Kγ 亚基的过表达增强了对 SDF1α/CXCL12 的细胞迁移反应,在 ZAP70+CLL 样本中观察到最强的效果。在趋化因子梯度内对细胞迁移进行显微镜跟踪显示,PI3Kγ 可在梯度感应中发挥作用,并影响细胞形态和 F-肌动蛋白极化。PI3Kγ 抑制也以类似于 idelalisib 的程度减少了 CLL 对基质细胞的黏附。这些发现首次提供了证据表明 PI3Kγ 在恶性 B 细胞中具有独特的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/1b63b3b98527/41375_2018_12_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/b53736fb3872/41375_2018_12_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/70caa99d3e48/41375_2018_12_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/5cb060f06485/41375_2018_12_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/9f6044ad2f1b/41375_2018_12_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/c9ff3a8caaa5/41375_2018_12_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/7c01893ac598/41375_2018_12_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/0616cec6d60d/41375_2018_12_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/1b63b3b98527/41375_2018_12_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/b53736fb3872/41375_2018_12_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/70caa99d3e48/41375_2018_12_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/5cb060f06485/41375_2018_12_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/9f6044ad2f1b/41375_2018_12_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/c9ff3a8caaa5/41375_2018_12_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/7c01893ac598/41375_2018_12_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/0616cec6d60d/41375_2018_12_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d727/6127087/1b63b3b98527/41375_2018_12_Fig8_HTML.jpg

相似文献

1
Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.PI3Kγ 和 PI3Kδ 在恶性 B 细胞迁移中发挥不同作用。
Leukemia. 2018 Sep;32(9):1958-1969. doi: 10.1038/s41375-018-0012-5. Epub 2018 Jan 31.
2
PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.PI3Kδ和PI3Kγ亚型在调节多发性骨髓瘤微环境中的促肿瘤信号传导方面具有不同的功能。
Blood Cancer J. 2017 Mar 10;7(3):e539. doi: 10.1038/bcj.2017.16.
3
Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.正常和白血病骨髓间充质基质细胞中磷酸肌醇 3-激酶 δ 的表达和功能。
Br J Haematol. 2019 Jun;185(5):883-887. doi: 10.1111/bjh.15865. Epub 2019 Mar 14.
4
Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.靶向PI3Kδ和PI3Kγ信号传导会破坏人类急性髓系白血病的生存以及骨髓基质细胞介导的保护作用。
Oncotarget. 2016 Jun 28;7(26):39784-39795. doi: 10.18632/oncotarget.9289.
5
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.不同亚型选择性特征的磷酸肌醇-3 激酶抑制剂抑制慢性淋巴细胞白血病细胞存活的功效。
Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.
6
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.在慢性淋巴细胞白血病细胞中,功能性1-磷酸鞘氨醇受体-1的表达受B细胞受体信号传导的抑制,而通过抑制PI3激酶δ可使其表达增加,但抑制脾酪氨酸激酶(SYK)或布鲁顿酪氨酸激酶(BTK)则不会增加其表达。
J Immunol. 2015 Mar 1;194(5):2439-46. doi: 10.4049/jimmunol.1402304. Epub 2015 Jan 28.
7
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.磷脂酰肌醇3激酶δ阻断增加B细胞中的基因组不稳定性。
Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.
8
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.磷酸肌醇 3-激酶 δ 抑制剂 CAL-101 抑制慢性淋巴细胞白血病中 B 细胞受体信号和趋化因子网络。
Blood. 2011 Sep 29;118(13):3603-12. doi: 10.1182/blood-2011-05-352492. Epub 2011 Jul 29.
9
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.磷酸肌醇-3-激酶(PI3K)-δ和γ抑制剂IPI-145(度维利塞)可克服PI3K/AKT/S6信号通路的信号,并促进慢性淋巴细胞白血病(CLL)细胞凋亡。
Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.
10
Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.发现新型喹唑啉酮衍生物作为高效且选择性的 PI3Kδ 和 PI3Kδ/γ 抑制剂。
Eur J Med Chem. 2018 May 10;151:9-17. doi: 10.1016/j.ejmech.2018.03.068. Epub 2018 Mar 23.

引用本文的文献

1
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.慢性淋巴细胞白血病发病机制中的B细胞受体信号传导及相关通路
Front Oncol. 2024 Feb 26;14:1339620. doi: 10.3389/fonc.2024.1339620. eCollection 2024.
2
Phosphoinositide Signaling in Immune Cell Migration.免疫细胞迁移中的磷酯酰肌醇信号转导。
Biomolecules. 2023 Nov 24;13(12):1705. doi: 10.3390/biom13121705.
3
Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus.

本文引用的文献

1
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.idelalisib联合奥法木单抗治疗既往治疗过的慢性淋巴细胞白血病的疗效和安全性:一项开放标签、随机3期试验。
Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4.
2
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.依鲁替尼治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。
Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.
3
Stability of Reference Genes for Messenger RNA Quantification by Real-Time PCR in Mouse Dextran Sodium Sulfate Experimental Colitis.
双重抑制磷酸肌醇 3-激酶 δ 和 γ 可减少狼疮小鼠模型中慢性 B 细胞活化和自身抗体产生。
Front Immunol. 2023 May 10;14:1115244. doi: 10.3389/fimmu.2023.1115244. eCollection 2023.
4
Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib.PI3Kγ 和 PI3Kδ 在套细胞淋巴瘤增殖和迁移中的作用,有助于 PI3Kγ/δ 抑制剂 duvelisib 的疗效。
Sci Rep. 2023 Mar 7;13(1):3793. doi: 10.1038/s41598-023-30148-3.
5
PI3K Targeting in Non-solid Cancer.针对非实体瘤的 PI3K 靶向治疗。
Curr Top Microbiol Immunol. 2022;436:393-407. doi: 10.1007/978-3-031-06566-8_17.
6
PI3K Isoforms in B Cells.B 细胞中的 PI3K 同工型。
Curr Top Microbiol Immunol. 2022;436:235-254. doi: 10.1007/978-3-031-06566-8_10.
7
Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.鉴定和验证与失巢凋亡相关的基因特征,以预测胶质母细胞瘤的临床特征、干性、IDH 突变和免疫滤过。
Front Immunol. 2022 Aug 25;13:939523. doi: 10.3389/fimmu.2022.939523. eCollection 2022.
8
PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.用于治疗慢性淋巴细胞白血病的PI3K抑制剂:现状与未来展望
Cancers (Basel). 2022 Mar 18;14(6):1571. doi: 10.3390/cancers14061571.
9
Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation.通过将基于机器学习的虚拟筛选与多种蛋白质结构和生物评估相结合,发现新型选择性 PI3Kγ 抑制剂。
J Adv Res. 2021 Apr 20;36:1-13. doi: 10.1016/j.jare.2021.04.007. eCollection 2022 Feb.
10
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.联合使用 umbralisib(一种双重 PI3Kδ/CK1ε 抑制剂)治疗复发/难治性淋巴恶性肿瘤的安全性综合分析。
Blood Adv. 2021 Dec 14;5(23):5332-5343. doi: 10.1182/bloodadvances.2021005132.
实时定量PCR法检测小鼠葡聚糖硫酸钠实验性结肠炎中用于信使核糖核酸定量的内参基因稳定性
PLoS One. 2016 May 31;11(5):e0156289. doi: 10.1371/journal.pone.0156289. eCollection 2016.
4
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.PI3K通路:慢性淋巴细胞白血病中的临床抑制作用
Semin Oncol. 2016 Apr;43(2):260-4. doi: 10.1053/j.seminoncol.2016.02.004. Epub 2016 Feb 8.
5
Prognostic markers and standard management of chronic lymphocytic leukemia.慢性淋巴细胞白血病的预后标志物与标准管理
Hematology Am Soc Hematol Educ Program. 2015;2015:368-77. doi: 10.1182/asheducation-2015.1.368.
6
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.磷酸肌醇-3-激酶(PI3K)-δ和γ抑制剂IPI-145(度维利塞)可克服PI3K/AKT/S6信号通路的信号,并促进慢性淋巴细胞白血病(CLL)细胞凋亡。
Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.
7
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.不同亚型选择性特征的磷酸肌醇-3 激酶抑制剂抑制慢性淋巴细胞白血病细胞存活的功效。
Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.
8
Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.针对 PI3Kδ:慢性淋巴细胞白血病的新兴治疗方法及其他。
Med Res Rev. 2015 Jul;35(4):720-52. doi: 10.1002/med.21341. Epub 2015 Mar 11.
9
p84 forms a negative regulatory complex with p110γ to control PI3Kγ signalling during cell migration.p84与p110γ形成负调控复合物,以在细胞迁移过程中控制PI3Kγ信号传导。
Immunol Cell Biol. 2015 Sep;93(8):735-43. doi: 10.1038/icb.2015.35. Epub 2015 Mar 10.
10
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.在慢性淋巴细胞白血病细胞中,功能性1-磷酸鞘氨醇受体-1的表达受B细胞受体信号传导的抑制,而通过抑制PI3激酶δ可使其表达增加,但抑制脾酪氨酸激酶(SYK)或布鲁顿酪氨酸激酶(BTK)则不会增加其表达。
J Immunol. 2015 Mar 1;194(5):2439-46. doi: 10.4049/jimmunol.1402304. Epub 2015 Jan 28.